StemCell Therapy

Vision Care Market: Snapshot

World over, vision care has made some significant advances on the adoption of new population health approaches, especially in developed countries, underpinning the evolution of the vision care market. The goal is to achieve the care paradigm that promotes timely, effective, safe, and equitable treatment. More importantly, vision care must conform to standards of patient-centered care. This entire ecosystem needs to be engendered by standard clinical practice guidelines. Developed markets have been shifting toward the adoption of consistent evidence-based guidelines a key aspect in the expansion of the vision care market. An effective health approach hinges squarely on these evidence-based guidelines. The need has nudged the healthcare industry for increasing the awareness about comprehensive eye examinations in various parts of the world.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4416

Adoption of integrated model of care is a key part of comprehensive eye examinations. These examinations have occupied a key role in the vision care market for detect incipient eye diseases. That aside, such vision care also helps in diagnosing chronic conditions. A case in point is the use of comprehensive eye examinations in detecting multiple sclerosis and diabetes in adult population. Vision screening is different from an eye examination, nonetheless very crucial. In several countries, these screenings have helped identify potential vision problems and facilitate their early treatments. The significance is most evident in community settings. Thus, vision screening is emerging out as a vital diagnostic tool in children in various populations, opening new avenues in the vision care market. In recent years, the proponents of vision care underscore the importance of global partnerships and multisectoral collaboration.

Global Vision Care Market: Overview

An upcoming report on the global vision care market by TMR Research could be a valuable source of information for major stakeholders in the market. The report would offer a brilliant study of the market with its focus on market dynamics, segmentation, and geographical outreach. It could prove to be a useful guideline for players wanting to cement their position in the global vision care market.

Vision care or maintaining eye health are the major concerns globally. Vision-related diseases elevate the risk of blindness or significant vision loss. Good vision eases out daily important activities such as writing, reading, and watching. These also helps in communication, health, work, developmental learning and impacts in overall quality of life. Various factors such as chronic diseases, pollution, and unhealthy diets can affect in functioning of the eyes. Thus, plenty of products and treatments are developed to control vision related problems.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=4416<ype=S

Global Vision Care Market: Trends and Opportunities

Increasing usage of laptops, tablets, PCs, and phones in day-to-day lives, growing older population, and rising number of vision-related problems are believed to be driving the global vision care market. Apart from blindness, there are various vision related problems such as astigmatism, myopia, macular edema, retinal tears, and diabetic retinopathy. Growing demand from the population aged 65+ years, increasing healthcare industry, and rapid technological advancement in eye care products are expected to boost the global vision care market.

Although, declining eye care treatment rate, product design, and brand name are also projected to hinder the growth in the global vision care market. However, growing brand awareness and paradigm shift in the consumer behavior are projected to propel the global vision care market.

Global Vision Care Market: Market Potential

Growing advent of innovative product launches is expected to fuel the global vision care market. There are several products available for vision care such as contact lens, glass lens, contact lens solution, and IOLs. The incorporation of technology in developing vision care products increase efficiency, improves quality and precision of the final product, and reduces overall cost. Increasing demand for restoring normal vision with eyeglasses or contact lenses, cost-effectiveness in using vision care products instead of LASIK eye surgery, and rising advanced medical treatment are believed to be driving the global vision care market.

Global Vision Care Market: Regional Outlook

Region wise, there is a possibility of North America to lead the global vision care market as the region has witnessed rapid development in healthcare industry. Growing population suffering from eye related disorders, rapid technological advancement, and increasing healthcare industry with advanced infrastructure could also be fueling the global vision care market. The prominent countries in this region are US and Canada. Easy availability of glass lens and innovative product launches with the help of modern technology are projected to propel the global vision care market in these countries.

Global Vision Care Market: Competitive Dynamics

Some of the prominent players operating in the global vision care market are Johnson & Johnson, Valeant Pharmaceuticals, Novartis, ZEISS and The Cooper Companies. The upcoming TMR report would provide crucial information on their product offerings, market standing, and strategies for progress.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4416

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Link:
Vision Care Market Statistics, Trends, Analysis Size and Growth Factors by 2028 - Cole of Duty

ISLAMABAD:

Prime Minister Imran Khan on Friday ordered distribution of wheat from government warehouses in Punjab to the local markets to mitigate the effects of an impending flour crisis.

The bureaucracy had advised the premier to distribute wheat stocks from government warehouses in October.

However, the premier said, You should immediately bring wheat to the market and provide it at a cheaper price by setting up markets and sale points.

The premier added that if need be, wheat would be imported in October if needed.

Earlier, on Jun 9 it was reported that Pakistan is facing a shortfall of 1.4 million tons of wheat because of a decrease in yield, a development that is set to aggravate the existing flour crisis in the coming months.

The Federal Committee on Agriculture (FCA) was informed about the impending crisis during a meeting held on Wednesday, June 9, to review the Khareef season.

The wheat production target last year was set at 27 million tonnes. This year, there is a shortfall of 1.4 million tonnes and 79.95pc of the procurement target has been achieved.

Speaking during the meeting, Federal National Food Security and Research Minister Syed Fakhar Imam stressed the need to increase wheat production.

We need a breakthrough in high-yield wheat variety through genetic engineering, he added.

Our country has the best irrigation system which is not being used properly. Wheat is grown on 36pc of the countrys cultivated area.

Food Security Commissioner Dr Waseem informed the participants of the meeting that after many years, the country had exceeded the chickpea production target of 540,000 tonnes.

This year, there will be saving of Rs87 million as there will be less chickpea import, he added.

Potato production for the current year is 4.43 million tonnes against 4.4 million tonnes recorded last year. Balochistan also recorded a bumper crop of tomato this year.

Imam said there was a need to increase the production of oil seeds (sunflower, canola, rosehip and mustard).

The Indus River System Authority representative informed the participants of the meeting that there would 9pc more water available for Khareef season this year.

Originally posted here:
PM Imran orders distribution of wheat from government warehouses - The Express Tribune

Opinions of Thursday, 9 July 2020

Columnist: Joy Adzovie

File photo: Some GM crops

Genetically Modified Crops (GM crops) have generated a lot of controversies over the years. They have sparked debates among farmers and consumers alike with people always particularly paying attention to labelled GM and non-GM commodities on the market.

Some describe it as genetic modification. Some call it genetic engineering. Some call them genetically modified organisms (GMOs). Others describe them as biotechnology products, although biotechnology is a broader term. But all of them refer to the same thing.

A lot of ethical concerns have arisen about GM technology over the years. A very common claim made by some anti-GM activists is that you cannot play God which implies that scientists are defying the natural order of creation. Others are concerned about possible health risks associated with the consumption of GM foods although they have been proven scientifically to be safe, 20 years after their introduction.

In fact, in countries like USA, Brazil and South Africa, more than 80% of all soya beans, maize and cotton are GM crops. But there has been no single evidence of any of these crops negatively impacting the health of consumers in those countries. Before GM food is released for consumption, it is subjected to rigorous scrutiny which has zero tolerance for errors.

So, what exactly are GM crops?

In a bid to optimize yield, farmers have been breeding suitable varieties of crops through conventional selection for several centuries. This has made most wild ancestors of crops such as teosinte of maize go into extinction leaving the elite cultivars which look bigger and develop more desirable traits over the generations.

This method of breeding is known as selective breeding or artificial selection which is globally accepted but currently inefficient to feed a fast-growing population anticipated to reach 9.6 billion in the next couple of decades.

The exponential rise in population is inversely related to available land area hence the need for a more strategic approach to efficiently utilize the limited land resource to feed the growing global population. Also, pests and diseases, climate change, amidst other abiotic factors severely constrain crop production.

Biotechnology (which includes genetic modification) is an applied science that harnesses the natural biological capabilities of microbial, plants and animal cells for the benefit of mankind. It has changed the quality of life through improved medicine, diagnostics, agriculture and waste management, as well as offered opportunities for innovation and discoveries.

Genetic engineering is used to efficiently and precisely modify targeted plants using advanced biotechnological techniques. Advances in molecular biology have helped eliminate certain gaps in breeding such as reducing time to successfully introduce (introgress) a gene of interest into a commercial crop variety through a process called speed breeding and eradicating linkage drags associated with conventional breeding. The principle is a simple one.

To genetically improve or enhance a crop such as sweet potato which is susceptible to nematode attack, another crop such as tomato that is resistant to nematode attack is identified and the gene of interest is isolated. The gene isolated from the tomato is then introduced into the sweet potato. The host plant becomes a transgenic or genetically modified plant which expresses the desired trait (resistance to nematode) in subsequent generations.

Genetic engineering has had several uses such as in biofortification of crops to increase the concentration and availability of nutrients in crops hence solving hidden hunger problem faced by several African countries. The technology has also been used in the enhancement of plant architecture to optimize land usage and increase yield per area of land cultivated; and improved crops with heightened tolerance or resistance to both biotic and abiotic stresses including diseases and weather.

Benefits of GM crops

Some analysis shows that between 1996 and 2015, GM technology increased global production of corn by 357.7 million tons, soybean by 180.3 million tons, cotton fiber by 25.2 million, and canola by 10.6 million tons. GM crops also significantly reduced the use of agricultural land due to this higher productivity.

In 2015 alone, they prevented almost 20 million hectares from being used for agricultural purposes, thus reducing the environmental impact of cultivating forests or wildlands. This is a great environmental benefit derived from higher agricultural yield.

Unfortunately, in Africa, only a few countries including South Africa and South Sudan have allowed for the growing of GM crops and are enjoying from these benefits. Ghana has not allowed for the local production of GM crops although parliament passed a law in 2011 to allow for their introduction.

Genetic engineering is a viable way to eradicate hunger and ensure food security in the coming decades hence is pivotal to achieving Sustainable Development Goal (SDG) 2 on eliminating hunger. Yield losses due to changing or fluctuating climate, pests, and diseases, drought, acidic or saline soils and, heat stress can all be remedied by growing genetically modified crops. GM technology is a blessing to mankind and promises a hunger-free future especially in such unsettling times with the COVID-19 pandemic. Lets embrace it.

Joy Adzovie

Teaching and Research Assistant - University of Ghana

BSc. Agriculture- University of Ghana

GhanaWeb is not responsible for the reportage or opinions of contributors published on the website. Read our disclaimer.

Send your news stories to and via WhatsApp on +233 55 2699 625.

Original post:
Genetically Modified Crops: The solution to global food insecurity - GhanaWeb

ISLAMABAD:

Prime Minister Imran Khan on Friday ordered distribution of wheat from government warehouses in Punjab to the local markets to mitigate the effects of an impending flour crisis.

The bureaucracy had advised the premier to distribute wheat stocks from government warehouses in October.

However, the premier said, You should immediately bring wheat to the market and provide it at a cheaper price by setting up markets and sale points.

The premier added that if need be, wheat would be imported in October if needed.

Earlier, on Jun 9 it was reported that Pakistan is facing a shortfall of 1.4 million tons of wheat because of a decrease in yield, a development that is set to aggravate the existing flour crisis in the coming months.

The Federal Committee on Agriculture (FCA) was informed about the impending crisis during a meeting held on Wednesday, June 9, to review the Khareef season.

The wheat production target last year was set at 27 million tonnes. This year, there is a shortfall of 1.4 million tonnes and 79.95pc of the procurement target has been achieved.

Speaking during the meeting, Federal National Food Security and Research Minister Syed Fakhar Imam stressed the need to increase wheat production.

We need a breakthrough in high-yield wheat variety through genetic engineering, he added.

Our country has the best irrigation system which is not being used properly. Wheat is grown on 36pc of the countrys cultivated area.

Food Security Commissioner Dr Waseem informed the participants of the meeting that after many years, the country had exceeded the chickpea production target of 540,000 tonnes.

This year, there will be saving of Rs87 million as there will be less chickpea import, he added.

Potato production for the current year is 4.43 million tonnes against 4.4 million tonnes recorded last year. Balochistan also recorded a bumper crop of tomato this year.

Imam said there was a need to increase the production of oil seeds (sunflower, canola, rosehip and mustard).

The Indus River System Authority representative informed the participants of the meeting that there would 9pc more water available for Khareef season this year.

Read this article:
PM orders to bring wheat from government warehouse to general ma - The Express Tribune

The National Environment Management Authority (NEMA) plans to draft regulations that will guide the environmental release of genetically modified organisms.

Kasese district chairman leading a team that visited Mubuku GM cassava trial garden. PHOTOS: Prossy Nandudu

The National Environment Management Authority (NEMA) plans to draft regulations that will guide the environmental release of genetically modified organisms.

Under the revised Act of 2019, NEMA was given the mandate to regulate GMOs in the environment although the regulations were not made, until the Genetic Engineering Regulatory Act (GERA) that is before parliament is passed into law to give details on the regulatory process.

This was revealed by the executive director NEMA, Dr.Tom Okurut during a meeting organised by the Science Foundation for Livelihoods and Development (SCIFODE) at a monthly media bio cafe, on NEMA Act 2019 emerging regulations and guidelines on Wednesday.

"In the absence of a specific law for GMO regulation, we should move to draft regulations and guidelines, we didn't want to go first, now that it has stayed, we cannot delay, we must start because GMOs are already with us," said Okurut.

To ensure that the process takes shape, Okurut said they're in talks stakeholders such as the Ministry of Science Technology and Innovations (MOSTI), Uganda National Council for Science and Technology (UNCST), researchers among others to secure funding for the process.

According to Okurut, the NEMA Act 1995 had omissions especially on aspects such as oil and gas industry waste, electronic waste, and management of GMOs.

He, however, adds that these have since been catered for in the amended act of 2019, apart from the aspect of GMOs that we are supposed to make laws that will regulate it. But for NEMA to make the regulations, they had to wait for the GERA bill to be passed into law, an issue which is not yielding results.

"There are still pseudo scientists peddling lies about the technology without taking time to understand the basic science used by researchers in developing these products and we need the law to regulate the use, entry, consumption of all products from GMOs," Okurut said.

Okurut was backed by the director of regulation and biosafety at the Ministry of Science Technology and Innovations, Dr.James Kasigwa who seconded NEMA to use the amended act and regulate GMOs.

"Since we don't have a dedicated law, we can make use of NEMA act to have a stop-gap, issues of GMOs are real. Kenya now plants genetically modified cotton, they are about to release cassava and our borders are porous, what is in Kenya, will find its way into Uganda. Let us leverage any provisions in NEMA to have anything workable to put in place a regulatory framework," added Kasigwa.

Dr. Kasigwa noted that MOSTI is willing to cooperate with NEMA to ensure that a regulatory framework is in place

Currently, the agriculture sector is faced with the challenge of pests and diseases and climate change which are threatening many crops like bananas devastated by the bacterial wilt, Maize production suffers from drought-related insect pests among others.

"Fortunately many of these have been addressed through biotechnology and are in research fields waiting for regulation to be availed to the farming community to improve our productivity and competitiveness," added Isaac Ongu, the executive director of Scifode.

Follow this link:
Nema To Draft Biosafety Regulations And Guidelines - New Vision

The Genome Editing market report by Reports and Data provides an extensive overview of the vital elements of the Genome Editing market and factors such as drivers, restraints, latest trends, regulatory scenario, competitive landscape, technological advancements, and others. This is the latest report covering the current COVID-19 scenario. The coronavirus pandemic has greatly affected every industry worldwide. It has brought along various changes in market conditions. The rapidly changing market scenario and the initial and future assessment of the impact are covered in the research report. The report discusses all the major aspects of the market with expert opinions on the current status, along with historical data.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete [emailprotected] https://www.reportsanddata.com/sample-enquiry-form/1052

In market segmentation by manufacturers, the report covers the following companies-

Thermo Fisher Scientific Inc., Merck KGaA, GenScript, Horizon Discovery Group Plc, Integrated DNA Technologies, Inc, Lonza, New England Biolabs and Sangamo Therapeutics, Inc.

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Key Factors Explained In The Report:

Genome Editing product types, applications, geographies, and end-user industries are the key market segments that are comprised in this study. The report speculates the prospective growth of the different market segments by studying the current market standing, performance, demand, production, sales, and growth prospects existing in the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Genome Editing sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In market segmentation by types of Genome Editing , the report covers-

In market segmentation by applications of the Genome Editing , the report covers the following uses-

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.reportsanddata.com/discount-enquiry-form/1052

Geographically, this report studies the top producers and consumers in these key regions:

North America

Europe

China

Japan

Southeast Asia

India

Objectives of the study:

Our panel of expert analysts specializing in the value chain has conducted an exhaustive, industry-wide study to offer readers accurate insights into the future of the Genome Editing market and give key market players authentic information derived via both primary and secondary sources of data collection. Additionally, the report also comprises of inputs from our consultants, which can help companies make the most of the available market opportunities. It also offers a detailed breakdown of the sales of Genome Editing and the factors that could potentially influence the growth of the industry. The information provided in this report will be able to help readers capitalize on the available growth prospects.

The Genome Editing market research covers a detailed analysis of the following data:

BROWSE THE COMPLETE REPORT AND TABLE OF [emailprotected] https://www.reportsanddata.com/report-detail/genome-editing-market

Key Questions Answered:

Inconclusion, the Genome Editing Market report is a reliable source for accessing the Market data that will exponentially accelerate your business. The report provides the principal locale, economic scenarios with the item value, benefit, supply, limit, generation, request, Market development rate, and figure and so on. Besides, the report presents a new task SWOT analysis, speculation attainability investigation, and venture return investigation.

David is an Experience Business writer who regularly contribute to the blog, He specializes in manufacturing news

Tags: Genome Editing IndustryGenome Editing MarketGenome Editing Market 2020Genome Editing Market forecastGenome Editing Market growthGenome Editing Market shareGenome Editing Market sizeGenome Editing Market trend

More:
Genome Editing Market Emerging Trends, Business Opportunities, Segmentation, Production Values, Supply-Demand, Brand Shares and Forecast 2020-2027 |...

FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Companys Investigational New Drug (IND) application for FT819, an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy. The Company plans to initiateclinical investigation of FT819for the treatment of patients with relapsed / refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL).

The clearance of our IND application for FT819 is a ground-breaking milestone in the field of cell-based cancer immunotherapy. Our unique ability to produce CAR T cells from a clonal master engineered iPSC line creates a pathway for more patients to gain timely access to therapies with curative potential, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. Four years ago, we first set out under our partnership with Memorial Sloan Kettering led by Dr. Michel Sadelain to improve on the revolutionary success of patient-derived CAR T-cell therapy and bring an off-the-shelf paradigm to patients, and we are very excited to advance FT819 into clinical development.

FT819 was designed to specifically address several limitations associated with the current generation of patient- and donor-derived CAR T-cell therapies. Under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, and Head, Gene Expression and Gene Transfer Laboratory at MSK, the Company incorporated several first-of-kind features into FT819 including:

The multi-center Phase 1 clinical trial of FT819 is designed to determine the maximum tolerated dose of FT819 and assess its safety and clinical activity in up to 297 adult patients across three types of B-cell malignancies (CLL, ALL, and NHL). Each indication will enroll independently and evaluate three dose-escalating treatment regimens: Regimen A as a single dose of FT819; Regimen B as a single dose of FT819 with IL-2 cytokine support; and Regimen C as three fractionated doses of FT819. For each indication and regimen, dose-expansion cohorts of up to 15 patients may be enrolled to further evaluate the clinical activity of FT819.

At the American Association for Cancer Research (AACR) Virtual 2020 Meeting, the Company presented preclinical data demonstrating FT819 is comprised of CD8 T cells with uniform 1XX CAR expression and complete elimination of endogenous TCR expression. Additionally, data from functional assessments showed FT819 has antigen-specific cytolytic activity in vitro against CD19-expressing leukemia and lymphoma cell lines that is comparable to that of healthy donor-derived CAR T cells, and persists and maintains tumor clearance in the bone marrow in an in vivo disseminated xenograft model of lymphoblastic leukemia.

Fate Therapeutics has an exclusive license for all human therapeutic use to U.S. Patent No. 10,370,452 pursuant to its license agreement with MSK1, which patent covers compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell including an iPSC. In addition to the patent rights licensed from MSK, the Company owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control.

1 Fate Therapeutics haslicensedintellectual propertyfrom MSK on which Dr. Sadelain is aninventor.As a result of the licensing arrangement, MSK has financial interests related to Fate Therapeutics.

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates and clinical studies, the Companys progress, plans and timelines for the clinical investigation of its product candidates, the therapeutic potential of the Companys product candidates including FT819, and the Companys clinical development strategy for FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of difficulties or delay in the initiation of any planned clinical studies, or in the enrollment or evaluation of subjects in any ongoing or future clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of FT819 may not be replicated in ongoing or future clinical trials or studies, and the risk that FT819 may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

See original here:
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy - GlobeNewswire

Nanomedicine Market Overview 2020 2025

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The risingtechnology in Nanomedicine Marketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/91246

Key Competitors of the Global Nanomedicine Market are: , GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A,

Historical data available in the report elaborates on the development of the Nanomedicine on national, regional and international levels. Nanomedicine Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Major Applications of Nanomedicine covered are:Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

This study report on global Nanomedicine market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://reportsinsights.com/discount/91246

The fundamental purpose of Nanomedicine Market report is to provide a correct and strategic analysis of the Nanomedicine industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Nanomedicine market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Nanomedicine-Market-91246

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Read the original here:
New Comprehensive Report on Nanomedicine Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like - Jewish Life News

The federal government may continue to pay for controversial human embryonic stem cell research, a federal appeals court ruled Friday.

The three-judge panel says the government has correctly interpreted a law that bans the use of federal funds to destroy human embryos for research. The ruling is unlikely to put the issue to rest and one of the judges pleaded for Congress to make clear what the government should and should not be able to do.

The hard-to-understand case pits science against mostly religious arguments against using embryos in medical research. It's even more confusing because there are so many differenlt types of cells called stem cells.

Dr. James Sherley of Boston Biomedical Research Institute and Theresa Deisher of AVM Biotechnology in Seattle, who both do research using adult stem cells and oppose the use of human embryonic stem cells, sued in 2009. They said federal guidelines violate the law and would harm their work by increasing competition for limited federal funding.

Its been back and forth in the federal courts since then, and Sherley has vowed to take the case all the way to the Supreme Court.

The embryonic stem cells at issue are the bodys master cells. Found in days-old embryos, they are the source of all the cells and tissues in the body blood, brain, bone and muscle. Researchers are studying them to investigate how disease develops and are using some as transplants to treat diseases from Parkinsons to cancer. They are being tested in people to repair spinal cord injuries and as a possible cure for some forms of blindness.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Opponents of the research say its unacceptable to destroy a human embryo to get the cells. The 1996 Dickey-Wicker amendment, added by Congress to budget language every year, forbids the use offederal funds in research that destroys embryos.

When he was president, George W. Bush decided that the ban extended to human embryonic stem-cell research and greatly limited the federal program.

As one of his first acts after he entered office, President Barack Obama issued an executive order reversing this and encouraging the National Institutes of Health to pay for embryonic stem-cell research, so long as federal money wasnt used to directly make the stem cells. To get the cells, someone in a private lab using private money has to take apart the embryos usually left over from fertility clinics and destined for the trash can. Federal funds may be used to work with the cells that private labs make available.

On Friday, Judge Janice Rogers Brown, Judge David Bryan Sentelle, and Karen LeCraft Henderson of the U.S. Court of Appeals in Washington upheld an earlier court ruling throwing out the case. The law, they said permits federal funding of research projects that utilize already-derived embryonic stem cellswhich are not themselves embryosbecause no human embryo or embryos are destroyed in such projects.

As we have held before, the NIH interpretation of the statutes actual language is reasonable, they added.

"NIH will continue to move forward, conducting and funding research in this very promising area of science. The ruling affirms our commitment to the patients afflicted by diseases that may one day be treatable using the results of this research," NIH director Dr. Francis Collins said in a statement.

But Judge Brown wasnt entirely happy and asked Congress to please clear up the unclear wording of the Dickey-Wicker amendment and saying there are aspects of this case that should trouble the heart.

Given the weighty interests at stake in this encounter between science and ethics, relying on an increasingly Delphic, decade-old single paragraph rider on an appropriations bill hardly seems adequate, she wrote in Fridays opinion.

Supporters of the research said they were thrilled. This ensures that Americas best scientists can continue to move this work forward despite ideologically driven attempts to derail it, said Amy Rick, president of the Coalition for the Advancement of Medical Research.

There are other types of stem cells, including so-called adult stem cells, found in everyone's bodies. But scientists say they don't have the same powerful properties as embryonic stem cells. Labs are also working to re-program ordinary cells to behave like embryonic cells. A deeply divided Congress has decided not to weigh in on the issue until elections give one party or the other more power.

Maggie Fox, Senior Writer and Maggie Fox, Senior Writer

Read this article:
Court rules controversial stem cell research is legal

Young or old, hospitalized or asymptomatic, anyone who had COVID-19 is at risk, doctors say

***EDITORS NOTE: This article is Part 2 of 2. Please read Part 1, "Two weeks then gone? Not even close, say doctors about the lingering effects of COVID-19" by clicking here.

Following is a breakdown of some of the lingering effects of COVID-19 infections, according doctors and public health officials treating and examining cases.

Lungs

Since coronavirus is, at its most simplified, a respiratory virus, the lungs are typically where doctors say they see the most damage.

"I think lung fibrosis is the most worrying," said Dr. Michael Hamblin, associate professor and chemist specializing in Dermatology at Harvard Medical School. "The virus damages the lungs and you get this fibrosis which dramatically decreases your breathing capacity."

Lingering lung problems can affect people of all ages, said Dr. Aileen Marty, infectious disease specialist at Florida International University. She cites international research that shows some young people who report being asymptomatic actually have scar tissue in their lungs of which they are unaware.

"When studies have been done on people who feel great, about 67% of those people have changes on chest x-rays," she said. "CT scans will then refine those images, but changes on the CT scans are worse than the changes on the film."

Young people, in particular, may not realize they have diminished lung capacity until they are older, Marty said. And because the "majority" of COVID-19 hospitalizations in Florida right now are patients in their 30s and below, she said, a significant number of younger patients might be surprised to find themselves with breathing problems down the road.

"A young person may have 150% lung capacity, so if they lose 10-15%, they don't notice it; they feel great," she said. "The problem is, we dont know how much of that tissue gets scarred up. The virus is causing the damage, it's just their youth is not letting them perceive the damage."

Neurological disease

"Patients with COVID-19 are experiencing an array of effects on the brain, ranging in severity from confusion to loss of smell and taste to life-threatening strokes," said Dr. Robert Stevens, associate director of the Johns Hopkins Precision Medicine Center of Excellence for Neurocritical Care at Johns Hopkins Medicine in a June 4 report. "Younger patients in their 30s and 40s are suffering possibly life-changing neurological issues due to strokes."

Researchers at University of Bonn in Germany in a separate June 4 publication found some of these effects might be long lasting.

"Evidence strongly suggests that patients surviving COVID-19 are at high risk for subsequent development of neurological disease and in particular Alzheimers disease," they wrote.

Even those with no prior neurological problems could find themselves with issues, as detrimental effects from the virus put COVID-19 survivors "at risk for developing long-term neurological consequences either by aggravating a pre-existing neurological disorder or by initiating a new disorder," researchers said.

Neurological disease can be evidenced by cognitive decline, in which brain cells lose function or die, resulting in reduced intellectual or motor skills.

This condition affected one-third of hospitalized patients at the time of discharge, the researchers said. They also noted a growing number of "Kawasaki-like multisystem inflammatory syndromes now being recognized in children and teenagers" something they called "clinically striking."

Symptoms of Kawasaki disease include fever, rash, inflammation of the mouth, lips and throat and swelling of the hands and feet.

Blood clots, inflammation, heart

COVID-19-induced blood clots can result in strokes, heart attacks, pulmonary embolisms and kidney failure, as well as prevent oxygen flow to the hands and feet, Hamblin said.

"A lot of people ended up with necrosis of the extremities, so they have fingers and toes amputated because they turn black from COVID," he said. "Your blood inappropriately clots and you get no blood supply to the extremities and they die."

COVID-19-induced hyper-inflammation, which can result in respiratory failure or other severe problems, is also something he said doctors are working to understand.

One cause may be a "cytokine storm," which is when the body releases too many infection-fighting substances into the bloodstream.

"[The body] is trying to limit the infection and overcome the virus; however, it leads to an excessive inflammatory response rather than harming the virus," researchers said in a June 2 paper published in the U.S. National Library of Medicine.

University of Bonn researchers warn that inflammation can result in long-lasting, detrimental effects on the brain.

"The fact that systemic inflammation has been shown to promote cognitive decline and neurodegenerative disease makes it likely that COVID-19 survivors will experience neurodegeneration in the following years," they wrote.

While inflammation is observable, the underlying causes are less so, Hamblin said. And that is something doctors must determine if they hope to treat it effectively.

"The question is, is it the virus affecting the cells of the blood vessels or is it more like a serious infection where the immune cells go into overdrive and create systemic inflammation?" he said. "Local inflammation is not too bad, but systemic inflammation is very bad."

Kidneys

Kidneys act as a filter to eliminate toxins, waste and excess water from the body. Blood clots caused by COVID-19 can impair the kidneys ability function, leading to a host of problems throughout the the body.

"If the kidney function isn't normal, that's going to be a very significant issue over time," said Dr. C. John Sperati, kidney specialist and associate professor of medicine at Johns Hopkins Medicine.

Chronic kidney disease can lead to heart disease, as well as the need for dialysis. High potassium, acid, and protein levels; swelling of the arms and legs; and fluid in the lungs are indicators one might have kidney trouble, he said.

Those with pre-existing conditions are most likely to suffer kidney damage from COVID-19, but people with no previous kidney problems are also at risk, he said.

"In some cases 90% of ventilated patients in the ICU have gone on to develop kidney issues," he said. "If you were in the ICU, there is a 50-70 percent chance of kidney damage. Many of those will get better, but we dont have enough data to see how much recovery they will have."

Sperati said people tend to seek care for lung or heart problems before kidney trouble because the symptoms of the former tend to be more apparent. Unless kidney damage is severe, he said, many people might not know they have a problem until a blood test is performed.

"Its going to be one of those sort of silent killers thats under the surface," he warned. "If it resolves, good, but if it doesnt, that becomes a major health issue that needs to be addressed over time."

Psychological issues

Suffering through a COVID-19 infection, particularly for those who have been hospitalized or intubated, can be emotionally and mentally devastating, said Dr. Jessi Gold, assistant professor of psychiatry at Washington University in St. Louis, Missouri.

"When you leave the ICU, you can end up having dreams and not know if the things happened to you or not," she said. "You might have these really dark visions."

Like physical symptoms, psychological symptoms can persist even after the virus is gone.

"Just because you were in the ICU and lived, doesnt mean you are better," Gold said. "It can take months and months, if not years, and you can end up very different than your previous self."

Anxiety and depression, including Post Traumatic Stress Disorder, or PTSD, can accompany flashbacks, nightmares or a crushing sense of being unable to breathe, she said.

Even the most common stressors reported by ICU patients are exacerbated during COVID-19, she said. Feelings of isolation and worry are heightened because family and friends are typically not allowed to visit and nurses must avoid unnecessary contact with sick patients.

Those who convalesce at home can also be traumatized, she said, because fear of contracting the virus may cause those who would otherwise help out to steer clear, leaving the patient miserable and alone.

One area in need of additional research involves the idea that some psychological implications related to COVID-19 may be caused by factors beyond a persons individual experience while ill, Gold said.

"I wouldn't be surprised if there are things that we will find out over time where well see that the disease itself causes biological problems that affect the brain and your mood and how you are feeling," Gold said. "That it is not the circumstance the experience, stress, anxiety or trauma of it but that it is actually coming from the disease itself."

Click here to read Part 1, "Two weeks then gone? Not even close, say doctors about the lingering effects of COVID-19."

@WendyRhodesFL

wrhodes@pbpost.com

Visit link:
Lingering effects of COVID-19 on the lungs, heart, brain, kidneys and immune system - Palm Beach Post

A lot of scientific brain power and research dollars are being going to tests and treatments for the novel coronavirus. And much recent attention has been focused on antibody testing. Theres a lot of excitement, because the presence of antibodies in your blood can reveal if youve been infected previously with the virus and produced an immune response to fight it off. But beyond that basic finding, theres not much scientific evidence to translate what this means to your own health, as well as others.

Before I bust the biggest myths about the testing, its important to know exactly what antibodies are. Theyre proteins produced by the body that recognize and bind to a virus. Once this happens, a process is triggered, which inactivates the virus and eliminates it from the body. This is the bodys natural immune response to a viral infection.

And while the field of immunology and antibody response has been studied for decades and is well-defined for many viruses (like polio), when it comes to COVID-19, the whole process is not well understood because its a never-seen-before virus.

So before you consider going for a COVID-19 antibody test, its time to do a little myth-busting to first understand what your results actually can tell you. Remember to always talk with your doctor for personal guidance.

MYTH #1: All antibody tests provide reliable information

Fact: Only a fraction of the tests advertised meet FDA specifications. At first, the FDA didnt require manufacturers to get authorization from the agency, making test quality very inconsistent. But this changed on May 4, when the FDA announced that all companies had to submit validation data and apply for emergency utilization authority (EUA) to sell a test. Fewer than 20 of the dozens of tests available have achieved that so far. Always look for a test that documents accuracy of at least 99 percent, and ideally 99.5 percent. The FDA lists this information on their website.

Get the knowyourvalue newsletter.

MYTH #2: All antibody tests measure the same thing

Fact: Different tests measure different types of antibodies, with some more specific than others. A positive test only indicates that you were infected at some point in the past.

The typical first responder antibody of the immune system is called IgM (immunoglobulin M). Another type, IgA, found in the lining of the respiratory and digestive tracts contributes to the early response. The body next produces IgG (immunoglobulin G), an antibody better able to recognize and target a specific virus. The IgM component typically disappear after a few months, while the IgG lasts longer, and is likely the most useful measure for longer term immunity.

Only the small number of antibody tests receiving EUA authorization from the FDA are reliable, as they are at least 99 percent accurate and specific for particular antibodies directed against COVID-19. Some tests are measuring other kinds of viral antibodies.

Otherwise, you are open to a greater likelihood of a result that is a false positive (you really DONT have antibodies) or a false negative (you really DO have them). Either false result doesnt help make informed health decisions.

MYTH #3: If you have antibodies, you are protected from getting the virus again

Fact: There is no evidence that a positive antibody test protects you from another infection.With the presence of antibodies, there is some protection, but theres still no information on how long that protection lasts and what level of antibodies you need to get that protection. A reliable antibody test only indicates if your body has produced antibodies to a previous infection. It also does NOT tell you if you have an active infection.

MYTH #4: You can go to your doctors office for a test

Fact: An antibody test cannot be done at a doctors office. You need to go to a large laboratory chain like Quest Diagnostics or LabCorps. And you can request the test via your primary care doctor, or schedule it directly. Its important to check with your insurance carrier for coverage.

And remember that this is a blood test, with a scheduled blood draw at the lab. While there is a home test available, using a pin-prick blood test, the accuracy is uncertain and not recommended at this time.

Madelyn Fernstrom, PhD is NBC News health editor. Follow her on Twitter @drfernstrom.

See the article here:
Busted! The 4 biggest myths about COVID-19 antibody testing - NBC News

Lack of sleep can increase risk of high blood pressure

Lack of sleep or sleep deprivation can play havoc with your health. For starters, it can negatively affect your immunity and may interrupt with your weight loss goals. Not sleeping well for nights in a row can affect your mental abilities as well. Getting less than seven hours of sleep on a regular basis can lead to health consequences that affect your entire body. Digestive system, respiratory system, immune system and central nervous system can all be affected by lack of sleep or sleep deprivation.

Insufficient sleep has been linked to a number of health problems. Here are some of them.

1. Weight gain: Not sleeping well for even one night can put your body in sleep debt. What's worse is that it may increase cravings and appetite. Sleep deprivation disturbs the balance of chemicals which signal the brain that you are full. As a result, you are likely to overeat even if you are full. This may lead to weight gain, obesity and other health risks linked to being overweight.

2. Low libido: Not sleeping well can lower your sex drive. The decrease in libido in men maybe because of a drop in testosterone levels.

Also read:Disrupted Sleep And Your Relationship With Food: Know The Surprising Link

3. Diabetes risk: Body's release of insulin can be affected by lack of sleep. Insulin is the hormone which is required to regulate blood sugar levels. People who don't sleep sufficiently are likely to have higher blood sugar levels and are at higher risk of developing type 2 diabetes.

4. Weak immunity: Sleeping too less can affect immune system's ability to fight virus that cause cold, flu and other infections. It makes you more susceptible to getting sick on being exposed to germs.

5. Mood swings: Being sleep deprived for too long can make you short-tempered, moody and emotional. Being chronically sleep deprived can lead to anxiety and increase risk of depression.

6. Poor concentration and focus: Your thinking, problem-solving skills, concentration and creativity can be negatively affected if you are sleep deprived and haven't rested well.

Lack of sleep can affect your thinking, concentration and focusPhoto Credit: iStock

Also read:Losing Out On Sleep Amidst Lockdown? Milk, Eggs And Bajra Can Help

7. Poor balance: Balance and coordination can be negatively affected if you have not been sleeping well off late. It increases your risk of falls and accidents.

8. High blood pressure: Sleep deprivation needs to be taken seriously by hypertension patients. Sleeping for less than five hours at night increases your risk of getting high blood pressure.

9. Heart disease risk: High blood pressure is one of the top causes of heart disease. Sleep deprivation can also increase inflammation in the body, which can also increase risk of heart disease.

10. Poor memory: When you are asleep, the brain forms connections that can help you process and remember information. Not sleeping well can affect both short and long-term memory.

Also read:Do You Have Sleep Apnoea? Know The Symptoms; It May Cause Memory Loss, Depression

Working on your sleep and making time for it no matter how busy your life is, can help in preventing sleep deprivation.

Also read:Increased Stress, Disturbed Sleep And Other Risks Associated With Drinking Too Much Alcohol

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Follow this link:
Weak Immunity And 9 Other Risks Associated With Sleep Deprivation - NDTV

Dr. Rebecca Auer says the study could help experts understand why some COVID-19 patients are relatively asymptomatic while others end up in intensive care or die

OTTAWA A national clinical trial this summer will focus on protecting cancer patients against severe COVID-19 infectionby attempting to boost their compromised immune system.

Researchers from The Ottawa Hospital say they want to explore the potential of IMM-101, a preparation featuring a dead pathogen containing properties that can stimulate the "first-response arm" of the immune system.

Study lead Dr. Rebecca Auer, surgical oncologist and director of cancer research at the Ottawa Hospital, says it could help experts understand why some COVID-19 patients are relatively asymptomatic while others end up in intensive care or die.

"The difference it seems between these two different presentations has to do with how strong your innate, or your sort of non-specific, first-line defence immune system response is to the virus," Auer said Wednesday.

"And so we're hoping that by boosting and stimulating this innate immune response, particularly in those vulnerable patients that have a reduced immune response to begin with, we'd be able to prevent symptomatic infections and prevent serious infections."

Cancer patients are at much higher risk of severe complications from COVID-19 because chemotherapy, cancer surgeryand radiation treatments suppress innate immunity even further.

Auer points to an "urgent need" to protect them while the world waits for an effective COVID-19 vaccine, which could take another year or more to develop, test, and implement.

A successful trial could also protectcancer patientsagainst other respiratory infections as well as the coming flu season, says Auer, noting the threat of illness is a fairly big problem for those undergoing treatment.

"A study demonstrated that about 13 to 15 per centof cancer patients will have to delay or stop their treatment because of influenza during the average flu season," she says.

"And also cancer patients don't respond as well to the influenza vaccine every year because their immune system isn't as strong. So we think that the IMM-101 may in itself be able to help prevent symptomatic influenza infections."

Auer says IMM-101 has also been tested elsewhere for its anti-cancer properties and that, too, will be examined in this trial, although it's not the primary objective.

The researchers say the bacteria, Mycobacterium obuense, is safe to use in cancer patients because it has been killed by heat.

The Canadian study will recruit 1,500 patients currently receiving cancer treatment,and participants will be randomly assigned to receive either regular care, or regular care plus IMM-101.

Auer says the treatment would be administered as an injection in the arm, to be followed by two more booster shots.

Researchers will follow patients for a year, watching for any respiratory infections and monitoring whether the treatment works and how long it lasts.

The trials will take place in eight centres located in Ontario, British Columbia and Quebec.

Researchers saypeople interested in participating should speak with their cancer specialist.

Researchers from the Ottawa Hospital came up with the idea and worked with the Canadian Cancer Trials Group at Queen's University to design the trial.

Dr. Chris O'Callaghan of the Queen's University group notes cancer patients are also at greater risk of COVID-19 infection because they require regular medical care, making it difficult to adhere fully to public health guidelines.

"These patients are unable to practice social isolation due to the need to regularly attend hospital to receive critically important cancer treatment, says O'Callaghan, who will oversee the trial.

Auer says asuccessful trial of IMM-101 could also suggest usefulness in treating any patient with a reduced innate immune system, such as older patients with chronic illness.

She notes that the tuberculosis vaccine known as BCG which uses a similar formulation to IMM-101 but uses live bacteria instead of dead bacteria is being tested around the world to see if it can boost the immunity of health-care workers exposed to COVID-19.

Funding and in-kind support, valued at $2.8 million, comes from the Canadian Cancer Society, BioCanRx, the Ontario Institute for Cancer Research, The Ottawa Hospital Foundation, The Ottawa Hospital Academic Medical Organization, ATGen Canada/NKMax, and Immodulon Therapeutics, the manufacturer of IMM-101.

By Cassandra Szklarski in Toronto

This report by The Canadian Press was first published July 8, 2020.

The Canadian Press

Read the original post:
CANADA: Cancer trial to focus on protecting patients from COVID-19 infection - KitchenerToday.com

Erythritol Market Data Breakdown with Revenue and Gross Profit Analysis 2020-2026

The GlobalErythritolMarket report provides a detailed analysis of the market all key factors affecting global and regional markets, including drivers, imprisonment, threats, challenges, opportunities and industry-specific trends. This business research document puts forward an in-depth evaluation of each crucial aspect of the worldwide market that relates to the Erythritol Market size, market share, market growth factor, key vendors, revenue, top regions, industry trends, product demand, sales volume, capacity, cost structure, and expansion in the Erythritol Market. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Erythritol by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

The Erythritol market report comprises a competitive analysis of the key players functioning in the market and covers in-depth data related to the competitive landscape of the market and the recent strategies & products that will assist or affect the market in the coming years. The Erythritol Market is segmented by component, deception stack, deployment mode, organization size, industry vertical, and region.The Erythritol Market Report Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. The Erythritol Market report gives a top to bottom diagram of Product Specification, innovation, product type and production analysis considering major factors, such as Revenue, Cost, Gross and Gross Margin.

Get a Erythritol Market Report Sample Copy @https://www.industryandresearch.com/report/Global-Erythritol-Market-Analysis-2013-2018-and-Forecast-2019-2024/121969#samplereport

Global Erythritol Market Report Coverage

The global Erythritol market will reach xxx Million USD in 2019 and CAGR xx% 2020-2026. The insight has been added in the report to provide realistic overview of the industry, consist of Erythritol manufacturers data, i.e. shipment, price, revenue, gross profit, business distribution, etc., SWOT analysis, consumer preference, recent developments and trends, drivers and restrain factors, company profile, investment opportunity, demand gap analysis, forecast market size value/volume, services and product, Porters Five Models, socioeconomic factors, government regulation in Erythritol industry. Market players can use the report to peep into the future of the global Erythritol market and bring important changes to their operating style and marketing tactics to achieve sustained growth.

Market Competitive Analysis:Zibo ZhongShi GeRui Biotech, Zhucheng Dongxiao Biotechnology, Shandong Sanyuan Biotechnology, Jungbunzlauer, Cargill, Baolingbao Biologyare the major players operating in the global market for Erythritol. The business participants are extensively focusing on product innovations, new product launches, mergers, and acquisitions for expanding their geographic foothold and capturing greater market share. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments.

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.By Regions:* North America (The US, Canada, and Mexico)* Europe (Germany, France, the UK, and Rest of the World)* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)* Latin America (Brazil and Rest of Latin America.)* Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

Global Erythritol Market Type Segments:Erythritol Powder, Erythritol Granular

Global Erythritol Market Application Segments:Confectionery, Beverage, Personal Care, Health Care, Others

Research objectives of Erythritol Market:1. To study and analyze the global Erythritol consumption (value & volume) by key regions/countries, product type and application, history data from 2015 to 2019, and forecast to 2026.2. To understand the structure of Erythritol market by identifying its various subsegments.3. Focuses on the key global Erythritol manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.4. To analyze the Erythritol with respect to individual growth trends, future prospects, and their contribution to the total market.5. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).6. To project the consumption of Erythritol submarkets, with respect to key regions (along with their respective key countries).7. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.8. To strategically profile the key players and comprehensively analyze their growth strategies.

Key Features of the Report:* Key developments and product launches by the top players and brands* Key parameters which are driving the market* Key trends of the market* Challenges of market growth* What are the challenges being faced by the new entrants

Table of Contents:* Global Erythritol Market Overview* Economic Impact on Industry* Production, Revenue (Value), Price Trend by Type* Market Analysis by Application* Cost Analysis* Industrial Chain, Sourcing Strategy and Downstream Buyers* Marketing Strategy Analysis, Distributors/Traders* Market Effect Factors Analysis* Global Erythritol Market Forecast

Read Detailed Index report @https://www.industryandresearch.com/report/Global-Erythritol-Market-Analysis-2013-2018-and-Forecast-2019-2024/121969

In final conclusion, this Erythritol Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Request customize:-If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

NOTE:Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Contact Us @[emailprotected]

Read the original here:
Global Erythritol Industry Developments and Assessment 2020-2026 | Zibo ZhongShi GeRui Biotech, Zhucheng Dongxiao Biotechnology - Owned

Facial Injectable Marketreport covers the COVID 19 impact analysis on key drivers influencing market Growth, Opportunities, the Challenges and the Risks faced by key players and the Facial Injectable market as a whole. The complete profile of the worldwide top manufacturers like (Bloomega BioTechnology, Allergan, Merz Pharma, Bausch Health, Galderma, Integra Lifesciences, Tei Biosciences, Fibrogen) is mentioned such as Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Sales Volume, Sales Revenue, Consumption, Growth Rate, Import, Export, Supply, Future Strategies, and The Technological Developments that they are making are also included within this Facial Injectable market report. The historical data from 2012 to 2020 and forecast data from 2020 to 2026.

Get Free Sample PDF (including full TOC, Tables and Figures)of Facial Injectable[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2039429

In-Depth Qualitative Analyses Include Identification And Investigation Of The Following Aspects: Facial Injectable Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces.

Scope of Facial Injectable Market:Facial Injectable, also commonly known as Dermal Fillers, are the products used for aesthetic purposes such as anti-aging and enhancing the appearance of facial skin and help in a trending application known as bio-engineering or facial rejuvenation.

Geographically, North America dominated the facial injectable market driven by a high number of aged and adult population, higher awareness, higher spending on such treatment, presence of world class infrastructure and service providers and stringent guidelines in the region.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Hospitals Clinics Research Others

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Hyaluronic Acid Collagen Botulinum Toxin Polymers Particles

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2039429

Facial Injectable Market Regional Analysis Covers:

The Facial Injectable Market Report Can Answer The Following Questions:

Contact:

ResearchMozMr.Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

Read the original here:
Facial Injectable Market Trends and Forecast Analysis by Business Manufactures and Product Type-Bloomega BioTechnology, Allergan, Merz Pharma, Bausch...

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Link:
Stem Cell Therapy Market : Global Forecast over 2025 Cole of Duty - Cole of Duty

SAN DIEGO, July 8, 2020 /PRNewswire-PRWeb/ --R3 International is now offering effective stem cell therapy for Crohns disease, Ulcerative Colitis and IBD with a new program in Mexico. The new program provides up to 200 million stem cells for patients, with treatment starting at only $2975.

Millions of individuals worldwide suffer from chronic abdominal issues that affect every aspect of daily life and lead to difficulty with functioning. Traditional treatments are often insufficient and entail significant side effects.

According to R3 CEO David Greene, MD, MBA, "Stem cell therapy for Crohns, UC and IBD is not only safe and effective, but you don't have the bad side effects like you do with traditional drugs. We've been very successful in Mexico because the therapies are not only clinically and cost effective, but we offer very high numbers of stem cells for pricing exponentially less than the US, Panama or others!"

Studies on stem cell therapy for inflammatory diseases such as Crohns are showing that they are highly effective at regulating one's immune response (Nat Rev Nephrol 2018). This typically helps reduce flare ups and pain in patients, helping to increase quality of life tremendously.

Since R3 Stem Cell International opened in Tijuana, outcomes for these inflammatory conditions have been tremendous, with patients receiving anywhere from 30 million to 200 million stem cells.

The cells offered at R3 International come from a lab with a perfect safety record and quality assurance standards that exceed those of the FDA. No preservative is necessary, so the cell viability for the biologic exceeds 95% typically.

According to CEO Dr. Greene, "We made sure to partner with a lab that has a perfect safety record and only cultures cells between three and five generations. This means counts are high, and so is the potency of the cells!"

The treatment process starts with a free phone consultation with one of R3's licensed, experienced stem cell doctors. Once the treatment recommendation is made and the procedure is scheduled, the patient's designated concierge representative will assist with travel logistics. Transportation is included to and from the clinic from San Diego International Airport, which is only 20 minutes away.

Treatment starts at $2975 for 30 million live stem cells, and goes up $1000 for a total of 50 million. If a patient desires, a five day stay will include three treatments totaling 150 to 200 million stem cells. Or there is an option for four visits over a year as well, both starting at $8975 all inclusive.

To start the seamless process of obtaining treatment, visit for more information and call (888) 988-0515 to schedule the phone consultation.

SOURCE R3 Stem Cell International

The rest is here:
R3 International Now Offering Stem Cell Therapy Program for Crohns Disease, IBD and Ulcerative Colitis - Benzinga

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Stem Cell Therapy MarketIndustry / Sector Trends

Stem Cell Therapy Market size was valued at USD 7.8 billion in 2018 and is expected to witness 10.2% CAGR from 2019 to 2025.

U.S. Stem Cell Therapy Market Size, By Type, 2018 & 2025 (USD Million)

Rising prevalence of chronic diseases will positively impact the stem cell therapy market growth. Cardiovascular diseases, neurological disorders and other chronic conditions have resulted in high mortality over past few years. Conventional therapeutic methods and treatments are currently replaced due to lack of efficiency and efficacy. Recently developed stem cell therapies are capable of replacing defective cells to treat diseases that has reduced morbidity drastically. Therefore, people have now started relying on stem cell therapy that has long term positive effects.

Advancements in stem cell therapy in developed regions such as North America and Europe have boosted the industry growth. Since past few years, there have been several researches carried out for stem cell therapy. Currently developed stem cell therapies have shown positive outcomes in treatment of leukemia. Similarly, due to advancements in regenerative medicine, several other chronic conditions such as muscular dystrophy and cardiovascular diseases also have been cured. Aforementioned factors have surged the industry growth. However, high cost of allogenic stem cell therapy may hamper the industry growth to some extent.

Market Segmentation, Outlook & Regional Insights: Stem Cell Therapy Market

Stem Cell Therapy Market, By Type

Allogenic stem cell therapy segment held around 39% revenue share in 2018 and it is anticipated to grow substantially during analysis timeframe. Allogenic stem cell is available as off the shelf therapy and it is easily scalable that helps in providing treatment without delay. Moreover, the procedure includes culturing donor-derived immunocompetent cells that are highly effective in treatment of several diseases. Stem cells obtained in allogenic therapy are free of contaminating tumor cells. This reduces risk for disease recurrence that will surge its demand thereby, stimulating segment growth.

Autologous stem cell therapy segment is estimated to witness 10.1% growth over the forthcoming years. People usually prefer autologous stem cell therapy as it has minimum risk of immunological rejection. However, on introduction of allogenic stem cell therapy, demand for autologous stem cell therapy has declined as it is difficult to scale up. However, there are concerns regarding risk of cross contamination during large scale manufacturing of autologous stem cell lines that will impede segmental growth to some extent.

Stem Cell Therapy Market, By Application

Neurology segment was valued around USD 1.6 billion in 2018 and it is estimated that it will witness significant growth over the forthcoming years. Stem cells are used to replenish the disrupted neurological cells that helps in quick patient recovery. Pluripotent stem cells provide replacement for cells and tissues to treat Alzheimers, Parkinsons disease, cerebral palsy, amyotrophic lateral sclerosis and other neurodegenerative diseases. Thus, pivotal role of stem cells in treating life threatening neurological condition will escalate segment growth.

Cardiovascular segment will witness 10% growth over the analysis timeframe. Considerable segmental growth can be attributed to development in stem cell therapies that have enhanced recovery pace in patients suffering from cardiovascular diseases. Recently developed allogenic stem cell therapies are efficient and easily available that have reduced the mortality rates in cardiovascular patients. Above mentioned factors will propel cardiovascular segment growth in near future.

Germany Stem Cell Therapy Market Size, By Application, 2018 (USD Million)

Stem Cell Therapy Market, By End-users

Hospitals segment held over 56% revenue share in 2018 and it is anticipated to grow significantly in near future. Rising preference for stem cell therapies offered by hospitals proves beneficial for the business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On introduction and approval of any novel stem therapy, hospitals implement it immediately. Associations with research and academic institutes further helps hospitals to upgrade its stem cell treatment offerings that positively impacts the segmental growth.

Clinics segment is expected to grow at around 10% during the forecast timeframe. Clinics specializing in providing stem cell therapies are well-equipped with advanced medical devices and superior quality reagents required for imparting stem cell therapies. However, as clinics offer specialized stem cell therapies, their treatment cost is much higher as compared to hospitals that may reduce its preference.

Stem Cell Therapy Market, By Region

North America stem cell therapy market held around 41.5% revenue share in 2018 and it is estimated to grow substantially in near future. Increasing adoption of novel stem cell therapies will prove beneficial for regional market growth. Moreover, favourable government initiatives have positive impact on the regional market growth. For instance, government of Canada has initiated Strategic Innovation Fund Program that invests in research activities carried out for stem cell therapies enabling development in stem cell therapy. Above mentioned factors are expected to drive the North America market growth.

Asia Pacific stem cell therapy market is anticipated to witness 10.8% growth in near future owing to increasing awareness amongst people pertaining to benefits of advanced stem cell therapies. Additionally, favourable initiatives undertaken by several organizations will promote industry players to come up with innovative solutions. For instance, according to Pharma Focus Asia, members of Asia-Pacific Economic Cooperation collaborated with Life Sciences Innovation Forum to involve professionals having expertise in stem cell therapies from academia and research centers to promote developments in stem cell research. Thus, growing initiatives by organizations ensuring availability of new stem cell therapies will foster regional market growth.

Latin America Stem Cell Therapy Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Stem Cell Therapy Market

Key industry players in stem cell therapy market include Astellas Pharma Inc, Cellectis, Celyad, Novadip Biosciences, Gamida Cell, Capricor Therapeutics, Cellular Dynamics, CESCA Therapeutics, DiscGenics, OxStem, Mesoblast Ltd, ReNeuron Group and Takeda Pharmaceuticals. Chief industry players implement several initiatives such as mergers and acquisitions to sustain market competition. Also, receiving approvals for stem cell therapy products from regulatory authorities fosters companys growth. For instance, in March 2018, European Commission approved Takedas Alofisel that is off-the-shelf stem cell therapy. Product approval will help company to gain competitive advantage and capture market share.

Stem Cell Therapy Industry Viewpoint

Stem cells industry can be traced back to 1950s. In 1959 first animals were made by in-vitro fertilization by preserving the stem cells. Till 2000, research was being carried out on stem cells to study its therapeutic effect. In 2000, fund allocations were made to research on cells derived from aborted human foetuses. In the same year, scientists derived human embryonic stem cells from the inner cell mass of blastocytes. Later, in 2010, clinical trials for human embryonic stem cell-based therapy were initiated. As technology progressed, stem cell therapy for treating cancer were developed. However, due to ethical issues, the use of stem cells for curing diseases witnessed slow growth for few years. But as the regulatory scenario changed, people started preferring stem cell therapies due to its better efficacy. Stem cell therapy is in developing stage and has numerous growth opportunities in developing economies with high prevalence of chronic diseases.

Key Insights Covered: Exhaustive Stem Cell Therapy Market1. Market size (sales, revenue and growth rate) of Stem Cell Therapy industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Stem Cell Therapy industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Stem Cell Therapy industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Stem Cell Therapy industry.

Research Methodology: Stem Cell Therapy Market

Quick Read Table of Contents of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Excerpt from:
Stem Cell Therapy Market 2020: Consumption, Trends, Growth, Types,Industrial Applications, Leading Companies & Forecast till 2026 - Jewish Life...

Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.

The global stem cell therapy market is categorized based on various modes of treatment and by therapeutic applications. The treatment segment is further sub-segmented into autologous stem cell therapy and allogeneic stem cell therapy. The application segment includes metabolic diseases, eye diseases, immune system diseases, musculoskeletal disorders, central nervous system disorders, cardiovascular diseases and wounds and injuries.

Request For Report Sample:http://marketgrowthanalysis.com/reports/sample/217

Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

HospitalsAmbulatory Surgical Centers

Stem Cell Therapy Market, By Application:

OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System Disorders

Request For COVID-19 Analysis:http://marketgrowthanalysis.com/reports/enquiry/217

Stem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

In terms of geographic, North America dominates the global stem cell therapy market due to increased research activities on stem cells. The U.S. represents the largest market for stem cell therapy followed by Canada in North America. However, Asia is expected to show high growth rates in the next five years in global stem cell therapy market due to increasing population. In addition, increasing government support by providing funds is also supporting in growth of the stem cell therapy market in Asia. China and India are expected to be the fastest growing stem cell therapy markets in Asia.

Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are:Gamida CellReNeuron Group, plcOsiris Therapeutics, Inc.Stem Cells, Inc.Vericel Corporation.Mesoblast, Ltd.

Request For Report TOC:http://marketgrowthanalysis.com/reports/toc/217

More here:
Stem Cell Therapy Market Regulations and Competitive Landscape Outlook - 3rd Watch News

LOS ANGELES, United States: QY Research has recently published a report, titled Global Animal Stem Cell Therapy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Animal Stem Cell Therapy market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Animal Stem Cell Therapy market include: Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1932247/global-animal-stem-cell-therapy-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Animal Stem Cell Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Animal Stem Cell Therapy Market Segment By Type:

DogsHorsesOthers

Global Animal Stem Cell Therapy Market Segment By Application:

Veterinary HospitalsResearch Organizations

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Animal Stem Cell Therapy market.

Key companies operating in the global Animal Stem Cell Therapy market include Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1932247/global-animal-stem-cell-therapy-market

TOC

1 Study Coverage1.1 Animal Stem Cell Therapy Product Introduction1.2 Market by Type1.2.1 Global Animal Stem Cell Therapy Market Size Growth Rate by Type1.2.2 Dogs1.2.3 Horses1.2.4 Others1.3 Market by Application1.3.1 Global Animal Stem Cell Therapy Market Size Growth Rate by Application1.3.2 Veterinary Hospitals1.3.3 Research Organizations1.4 Study Objectives1.5 Years Considered 2 Executive Summary2.1 Global Animal Stem Cell Therapy Market Size Estimates and Forecasts2.1.1 Global Animal Stem Cell Therapy Revenue 2015-20262.1.2 Global Animal Stem Cell Therapy Sales 2015-20262.2 Animal Stem Cell Therapy Market Size by Region: 2020 Versus 20262.3 Animal Stem Cell Therapy Sales by Region (2015-2026)2.3.1 Global Animal Stem Cell Therapy Sales by Region: 2015-20202.3.2 Global Animal Stem Cell Therapy Sales Forecast by Region (2021-2026)2.3.3 Global Animal Stem Cell Therapy Sales Market Share by Region (2015-2026)2.4 Animal Stem Cell Therapy Market Estimates and Projections by Region (2021-2026)2.4.1 Global Animal Stem Cell Therapy Revenue by Region: 2015-20202.4.2 Global Animal Stem Cell Therapy Revenue Forecast by Region (2021-2026)2.4.3 Global Animal Stem Cell Therapy Revenue Market Share by Region (2015-2026) 3 Global Animal Stem Cell Therapy by Manufacturers3.1 Global Top Animal Stem Cell Therapy Manufacturers by Sales3.1.1 Global Animal Stem Cell Therapy Sales by Manufacturer (2015-2020)3.1.2 Global Animal Stem Cell Therapy Sales Market Share by Manufacturer (2015-2019)3.2 Global Top Animal Stem Cell Therapy Manufacturers by Revenue3.2.1 Global Animal Stem Cell Therapy Revenue by Manufacturer (2015-2020)3.2.2 Global Animal Stem Cell Therapy Revenue Share by Manufacturer (2015-2020)3.3 Global Animal Stem Cell Therapy Price by Manufacturer (2015-2020)3.4 Competitive Landscape3.4.1 Key Animal Stem Cell Therapy Manufacturers Covered: Ranking by Revenue3.4.2 Global Animal Stem Cell Therapy Market Concentration Ratio (CR5 and HHI) & (2015-2020)3.4.3 Global Animal Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.5 Global Animal Stem Cell Therapy Manufacturing Base Distribution, Product Type3.5.1 Animal Stem Cell Therapy Manufacturers Manufacturing Base Distribution, Headquarters3.5.2 Manufacturers Animal Stem Cell Therapy Product Type3.5.3 Date of International Manufacturers Enter into Animal Stem Cell Therapy Market3.6 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Company Profiles4.1 Medivet Biologics LLC4.1.1 Medivet Biologics LLC Corporation Information4.1.2 Medivet Biologics LLC Description, Business Overview4.1.3 Medivet Biologics LLC Animal Stem Cell Therapy Products Offered4.1.4 Medivet Biologics LLC Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.1.5 Medivet Biologics LLC Animal Stem Cell Therapy Revenue by Product4.1.6 Medivet Biologics LLC Animal Stem Cell Therapy Revenue by Application4.1.7 Medivet Biologics LLC Animal Stem Cell Therapy Revenue by Geographic Area4.1.8 Medivet Biologics LLC Animal Stem Cell Therapy Revenue by Sales Channel4.1.9 Medivet Biologics LLC Recent Development4.2 VETSTEM BIOPHARMA4.2.1 VETSTEM BIOPHARMA Corporation Information4.2.2 VETSTEM BIOPHARMA Description, Business Overview4.2.3 VETSTEM BIOPHARMA Animal Stem Cell Therapy Products Offered4.2.4 VETSTEM BIOPHARMA Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.2.5 VETSTEM BIOPHARMA Animal Stem Cell Therapy Revenue by Product4.2.6 VETSTEM BIOPHARMA Animal Stem Cell Therapy Revenue by Application4.2.7 VETSTEM BIOPHARMA Animal Stem Cell Therapy Revenue by Geographic Area4.2.8 VETSTEM BIOPHARMA Animal Stem Cell Therapy Revenue by Sales Channel4.2.9 VETSTEM BIOPHARMA Recent Development4.3 J-ARM4.3.1 J-ARM Corporation Information4.3.2 J-ARM Description, Business Overview4.3.3 J-ARM Animal Stem Cell Therapy Products Offered4.3.4 J-ARM Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.3.5 J-ARM Animal Stem Cell Therapy Revenue by Product4.3.6 J-ARM Animal Stem Cell Therapy Revenue by Application4.3.7 J-ARM Animal Stem Cell Therapy Revenue by Geographic Area4.3.8 J-ARM Animal Stem Cell Therapy Revenue by Sales Channel4.3.9 J-ARM Recent Development4.4 U.S. Stem Cell, Inc4.4.1 U.S. Stem Cell, Inc Corporation Information4.4.2 U.S. Stem Cell, Inc Description, Business Overview4.4.3 U.S. Stem Cell, Inc Animal Stem Cell Therapy Products Offered4.4.4 U.S. Stem Cell, Inc Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.4.5 U.S. Stem Cell, Inc Animal Stem Cell Therapy Revenue by Product4.4.6 U.S. Stem Cell, Inc Animal Stem Cell Therapy Revenue by Application4.4.7 U.S. Stem Cell, Inc Animal Stem Cell Therapy Revenue by Geographic Area4.4.8 U.S. Stem Cell, Inc Animal Stem Cell Therapy Revenue by Sales Channel4.4.9 U.S. Stem Cell, Inc Recent Development4.5 VetCell Therapeutics4.5.1 VetCell Therapeutics Corporation Information4.5.2 VetCell Therapeutics Description, Business Overview4.5.3 VetCell Therapeutics Animal Stem Cell Therapy Products Offered4.5.4 VetCell Therapeutics Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.5.5 VetCell Therapeutics Animal Stem Cell Therapy Revenue by Product4.5.6 VetCell Therapeutics Animal Stem Cell Therapy Revenue by Application4.5.7 VetCell Therapeutics Animal Stem Cell Therapy Revenue by Geographic Area4.5.8 VetCell Therapeutics Animal Stem Cell Therapy Revenue by Sales Channel4.5.9 VetCell Therapeutics Recent Development4.6 Celavet Inc.4.6.1 Celavet Inc. Corporation Information4.6.2 Celavet Inc. Description, Business Overview4.6.3 Celavet Inc. Animal Stem Cell Therapy Products Offered4.6.4 Celavet Inc. Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.6.5 Celavet Inc. Animal Stem Cell Therapy Revenue by Product4.6.6 Celavet Inc. Animal Stem Cell Therapy Revenue by Application4.6.7 Celavet Inc. Animal Stem Cell Therapy Revenue by Geographic Area4.6.8 Celavet Inc. Recent Development4.7 Magellan Stem Cells4.7.1 Magellan Stem Cells Corporation Information4.7.2 Magellan Stem Cells Description, Business Overview4.7.3 Magellan Stem Cells Animal Stem Cell Therapy Products Offered4.7.4 Magellan Stem Cells Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.7.5 Magellan Stem Cells Animal Stem Cell Therapy Revenue by Product4.7.6 Magellan Stem Cells Animal Stem Cell Therapy Revenue by Application4.7.7 Magellan Stem Cells Animal Stem Cell Therapy Revenue by Geographic Area4.7.8 Magellan Stem Cells Recent Development4.8 Kintaro Cells Power4.8.1 Kintaro Cells Power Corporation Information4.8.2 Kintaro Cells Power Description, Business Overview4.8.3 Kintaro Cells Power Animal Stem Cell Therapy Products Offered4.8.4 Kintaro Cells Power Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.8.5 Kintaro Cells Power Animal Stem Cell Therapy Revenue by Product4.8.6 Kintaro Cells Power Animal Stem Cell Therapy Revenue by Application4.8.7 Kintaro Cells Power Animal Stem Cell Therapy Revenue by Geographic Area4.8.8 Kintaro Cells Power Recent Development4.9 Animal Stem Care4.9.1 Animal Stem Care Corporation Information4.9.2 Animal Stem Care Description, Business Overview4.9.3 Animal Stem Care Animal Stem Cell Therapy Products Offered4.9.4 Animal Stem Care Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.9.5 Animal Stem Care Animal Stem Cell Therapy Revenue by Product4.9.6 Animal Stem Care Animal Stem Cell Therapy Revenue by Application4.9.7 Animal Stem Care Animal Stem Cell Therapy Revenue by Geographic Area4.9.8 Animal Stem Care Recent Development4.10 Animal Cell Therapies4.10.1 Animal Cell Therapies Corporation Information4.10.2 Animal Cell Therapies Description, Business Overview4.10.3 Animal Cell Therapies Animal Stem Cell Therapy Products Offered4.10.4 Animal Cell Therapies Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.10.5 Animal Cell Therapies Animal Stem Cell Therapy Revenue by Product4.10.6 Animal Cell Therapies Animal Stem Cell Therapy Revenue by Application4.10.7 Animal Cell Therapies Animal Stem Cell Therapy Revenue by Geographic Area4.10.8 Animal Cell Therapies Recent Development4.11 Cell Therapy Sciences4.11.1 Cell Therapy Sciences Corporation Information4.11.2 Cell Therapy Sciences Description, Business Overview4.11.3 Cell Therapy Sciences Animal Stem Cell Therapy Products Offered4.11.4 Cell Therapy Sciences Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.11.5 Cell Therapy Sciences Animal Stem Cell Therapy Revenue by Product4.11.6 Cell Therapy Sciences Animal Stem Cell Therapy Revenue by Application4.11.7 Cell Therapy Sciences Animal Stem Cell Therapy Revenue by Geographic Area4.11.8 Cell Therapy Sciences Recent Development4.12 Animacel4.12.1 Animacel Corporation Information4.12.2 Animacel Description, Business Overview4.12.3 Animacel Animal Stem Cell Therapy Products Offered4.12.4 Animacel Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)4.12.5 Animacel Animal Stem Cell Therapy Revenue by Product4.12.6 Animacel Animal Stem Cell Therapy Revenue by Application4.12.7 Animacel Animal Stem Cell Therapy Revenue by Geographic Area4.12.8 Animacel Recent Development 5 Breakdown Data by Type5.1 Global Animal Stem Cell Therapy Sales by Type (2015-2026)5.1.1 Global Animal Stem Cell Therapy Sales by Type (2015-2020)5.1.2 Global Animal Stem Cell Therapy Sales Forecast by Type (2021-2026)5.1.3 Global Animal Stem Cell Therapy Sales Market Share by Type (2015-2026)5.2 Global Animal Stem Cell Therapy Revenue Forecast by Type (2015-2026)5.2.1 Global Animal Stem Cell Therapy Revenue by Type (2015-2020)5.2.2 Global Animal Stem Cell Therapy Revenue Forecast by Type (2021-2026)5.2.3 Global Animal Stem Cell Therapy Revenue Market Share by Type (2015-2026)5.3 Animal Stem Cell Therapy Average Selling Price (ASP) by Type (2015-2026) 6 Breakdown Data by Application6.1 Global Animal Stem Cell Therapy Sales by Application (2015-2026)6.1.1 Global Animal Stem Cell Therapy Sales by Application (2015-2020)6.1.2 Global Animal Stem Cell Therapy Sales Forecast by Application (2021-2026)6.1.3 Global Animal Stem Cell Therapy Sales Market Share by Application (2015-2026)6.2 Global Animal Stem Cell Therapy Revenue Forecast by Application (2015-2026)6.2.1 Global Animal Stem Cell Therapy Revenue by Application (2015-2020)6.2.2 Global Animal Stem Cell Therapy Revenue Forecast by Application (2021-2026)6.2.3 Global Animal Stem Cell Therapy Revenue Market Share by Application (2015-2026)6.3 Animal Stem Cell Therapy Average Selling Price (ASP) by Application (2015-2026) 7 North America7.1 North America Animal Stem Cell Therapy Market Size YoY Growth 2015-20267.2 North America Animal Stem Cell Therapy Market Facts & Figures by Country7.2.1 North America Animal Stem Cell Therapy Sales by Country (2015-2026)7.2.2 North America Animal Stem Cell Therapy Revenue by Country (2015-2026)7.3 North America Animal Stem Cell Therapy Sales by Type7.4 North America Animal Stem Cell Therapy Sales by Application 8 Asia-Pacific8.1 Asia-Pacific Animal Stem Cell Therapy Market Size YoY Growth 2015-20268.2 Asia-Pacific Animal Stem Cell Therapy Market Facts & Figures by Region8.2.1 Asia-Pacific Animal Stem Cell Therapy Sales by Region (2015-2026)8.2.2 Asia-Pacific Animal Stem Cell Therapy Revenue by Region (2015-2026)8.3 Asia-Pacific Animal Stem Cell Therapy Sales by Type8.4 Asia-Pacific Animal Stem Cell Therapy Sales by Application 9 Europe9.1 Europe Animal Stem Cell Therapy Market Size YoY Growth 2015-20269.2 Europe Animal Stem Cell Therapy Market Facts & Figures by Country9.2.1 Europe Animal Stem Cell Therapy Sales by Country (2015-2026)9.2.2 Europe Animal Stem Cell Therapy Revenue by Country (2015-2026)9.3 Europe Animal Stem Cell Therapy Sales by Type9.4 Europe Animal Stem Cell Therapy Sales by Application 10 Latin America10.1 Latin America Animal Stem Cell Therapy Market Size YoY Growth 2015-202610.2 Latin America Animal Stem Cell Therapy Market Facts & Figures by Country10.2.1 Latin America Animal Stem Cell Therapy Sales by Country (2015-2026)10.2.2 Latin America Animal Stem Cell Therapy Revenue by Country (2015-2026)10.3 Latin America Animal Stem Cell Therapy Sales by Type10.4 Latin America Animal Stem Cell Therapy Sales by Application 11 Middle East and Africa11.1 Middle East and Africa Animal Stem Cell Therapy Market Size YoY Growth 2015-202611.2 Middle East and Africa Animal Stem Cell Therapy Market Facts & Figures by Country11.2.1 Middle East and Africa Animal Stem Cell Therapy Sales by Country (2015-2026)11.2.2 Middle East and Africa Animal Stem Cell Therapy Revenue by Country (2015-2026)11.3 Middle East and Africa Animal Stem Cell Therapy Sales by Type11.4 Middle East and Africa Animal Stem Cell Therapy Sales by Application 12 Supply Chain and Sales Channel Analysis12.1 Animal Stem Cell Therapy Supply Chain Analysis12.2 Animal Stem Cell Therapy Key Raw Materials and Upstream Suppliers12.3 Animal Stem Cell Therapy Clients Analysis12.4 Animal Stem Cell Therapy Sales Channel and Sales Model Analysis12.4.1 Animal Stem Cell Therapy Distribution Channel Analysis: Indirect Sales VS Direct Sales12.4.2 Animal Stem Cell Therapy Distribution Channel Analysis: Online Sales VS Offline Sales12.4.3 Animal Stem Cell Therapy Distributors 13 Market Dynamics13.1 Animal Stem Cell Therapy Market Drivers13.2 Animal Stem Cell Therapy Market Opportunities13.3 Animal Stem Cell Therapy Market Challenges13.4 Animal Stem Cell Therapy Market Restraints13.5 Porters Five Forces Analysis 14 Research Findings and Conclusion 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Author Details15.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Visit link:
Trending: Animal Stem Cell Therapy Market Analysis And In-Depth Research Growth By Major Players Forecast 2020 2026| Medivet Biologics LLC, VETSTEM...